MMP19 and Alport syndrome: ,30,31 The Alport Classification Working Group have established indications of RAS-I therapy for patients with Alport syndrome as follows: male patients with XL Alport syndrome and AR Alport syndrome at the timing of diagnosis; and female patients with XL Alport syndrome and AD Alport syndrome at the timing of diagnosis with hematuria and proteinuria.25